This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo


Topical formulation containing clobetasone butyrate, oxytetracycline (as calcium oxytetracycline) and nystatin.

Drugs List

  • clobetasone butyrate 0.05% and oxytetracycline 3% and nystatin 100000unit/g cream
  • TRIMOVATE cream
  • Therapeutic Indications


    Infected dermatoses responsive to topical corticosteroids

    Infected dermatoses responsive to topical corticosteroids where candidal or bacterial infection is present, suspected or likely including:
    Infected eczema
    Nappy rash
    Anogenital pruritus
    Seborrhoeic dermatitis



    1 application sparingly once or twice a day for up to seven days.


    1 application sparingly once or twice a day for up to seven days.


    Acne vulgaris
    Perioral dermatitis

    Precautions and Warnings


    May mask symptoms or signs of infections
    Exclude viral infection before treatment
    Avoid contact with eyes
    Avoid prolonged application to the face
    Cleanse skin thoroughly before applying occlusive dressings
    Do not dilute
    Risk of glaucoma if preparation enters eye
    Consider pseudomembranous colitis if patient presents with severe diarrhoea
    Adrenal suppression can occur in infants even without occlusion
    Long term use may cause adrenal suppression
    Prolonged use may cause atrophic skin changes
    Rebound effect may occur after cessation of treatment
    Discontinue at once if pseudomembranous colitis occurs
    Discontinue if hypersensitivity reactions occur
    Discontinue therapy and use antimicrobials if secondary infection occurs
    Avoid long-term use particularly in infants and children
    Maximum treatment 7 days unless on doctor's advice
    Advise patient residue on clothing/bedding may cause fire hazard
    Fire hazard: Keep away from naked flames and potential sources of ignition
    Nappy may act as an occlusive dressing
    Stains clothes and skin
    Stains hair

    Pregnancy and Lactation


    Use topical clobetasone with oxytetracycline and nystatin with caution during pregnancy.
    The manufacturer advises that use of clobetasone with oxytetracycline and nystatin should only be considered if the benefit to the mother outweighs the risk to the foetus.
    It is recommended to avoid using large amounts and for long periods of time if possible.
    Topical application of corticosteroids to pregnant animals can cause abnormalities of foetal development but the relevance to humans is unclear.


    Use topical clobetasone with oxytetracycline and nystatin with caution during breastfeeding.
    The manufacturer advises that clobetasone with oxytetracycline and nystatin should only be used if the expected benefit to the mother outweighs the risk to the infant. The product should not be applied to the breasts to avoid ingestion by the infant.
    If applied to the breast area, the area should be washed and dried prior to breastfeeding and the preparation applied afterwards.


    Advise patients to wash their hands after applying clobetasone with oxytetracycline and nystatin, unless it is the hands that are being treated.

    Advise patients residue on clothing/bedding may cause a fire hazard.

    Advise the patient that the product may stain skin, hair and clothes.

    Avoid contact with eyes.

    Side Effects

    Acne (at application site)
    Adrenal suppression
    Allergic contact dermatitis
    Atrophy (localised)
    Burning sensation (local)
    Cushing's syndrome
    Exacerbation of psoriasis
    Exacerbation of symptoms
    Hypersensitivity reactions
    Perioral dermatitis
    Pseudomembranous colitis
    Skin pigmentation changes
    Striae (irreversible)
    Thinning of skin


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2019

    Reference Sources

    Summary of Product Characteristics: Trimovate. Ennogen Healthcare Ltd. Revised November 2017.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.